Thromboembolism - An important manifestation of inflammatory bowel disease

American Journal of Gastroenterology

Volumn 99, Issue 10, 2004, Pages 1971-1973

  Quera, Rodrigo ^a,b   Shanahan, Fergus ^a,b  

^a UNIVERSITY COLLEGE CORK   (Ireland)

^b HOSPITAL CLÍNICO UNIVERSIDAD DE CHILE   (Chile)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE PHASE PROTEIN; ANTITHROMBIN III; AUTACOID; BIOCHEMICAL MARKER; BLOOD CLOTTING FACTOR 13; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 8; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C5A; FIBRINOGEN; FIBRINOPEPTIDE A; INTERLEUKIN 1; INTERLEUKIN 8; PLASMINOGEN ACTIVATOR INHIBITOR; PROTHROMBIN; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; TUMOR NECROSIS FACTOR; VON WILLEBRAND FACTOR;

CLINICAL FEATURE; DISEASE ASSOCIATION; ENTERITIS; HIGH RISK PATIENT; HUMAN; HYPERCOAGULABILITY; LABORATORY TEST; MORBIDITY; MORTALITY; MUCOSA INFLAMMATION; PATHOPHYSIOLOGY; PATIENT SELECTION; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SYMPTOM; THROMBOEMBOLISM; THROMBOPHILIA;

EID: 7044286356     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2004.40923.x     Document Type: Review

References (44)

1. Wakefield AJ, Dhillon AP, Rowles PM, et al. Pathogenesis of Crohn's disease: Multifocal gastrointestinal infarction. Lancet 1989;334:1057-62.
2. Sankey EA, Dhillon AP, Anthony A, et al. Early mucosal changes in Crohn's disease. Gut 1993;34:375-81.
3. Thompson N, Wakefield A, Pounder R. Inherited disorders of coagulation appear to protect against inflammatory bowel disease. Gastroenterology 1995;108:1011-5.
4. Papa A, Danese S, Gasbarrini A, et al. Review: Potential therapeutic applications and mechanisms of action of heparin in inflammatory bowel disease. Aliment Pharmacol Ther 2000;14:1403-9.
5. Talbot RW, Heppell J, Dozois RR, et al. Vascular complications of inflammatory bowel disease. Mayo Clin Proc 1986;61:140-5.
6. Novotny D, Rubin R, Slezak F, et al. Arterial thromboembolic complications of inflammatory bowel disease. Dis Colon Rectum 1992;35:193-6.
7. Jackson LM, O'Gorman PJ, O'Connell CC, et al. Thrombosis in inflammatory bowel disease: Clinical setting, pro-coagulant profile and factor V Leiden. Q J Med 1997;90: 183-8.
8. Oldenburg B, Fijnheer R, van der Griend R. Homocysteine in inflammatory bowel disease: A risk factor for thromboembolic complications? Am J Gastroenterol 2000;95:2825-30
9. Solem CA, Loftus EV, Tremaine WJ, et al. Venous thromboembolism in inflammatory bowel disease. Am J Gastroenterol 2004;99:97-101.
10. Miehsler W, Reinisch W, Valic E, et al. Is inflammatory bowel disease an independent and disease specific risk factor for thromboembolism? Gut 2004;53:542-8.
11. Bernstein CN, Blanchard JF, Houston DS, et al. The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease: A population-based cohort study. Thromb Haemost 2001;85:430-4.
12. Collins CE, Rampton DS. Review article: Platelets in inflammatory bowel disease-pathogenic role and therapeutic implications. Aliment Pharmacol Ther 1997;11:237-47.
13. Webberley MJ, Hart MT, Melikian V. Thromboembolism in inflammatory bowel disease: Role of platelets. Gut 1993;34:247-51.
14. Lakatos L, Pandur T, David G, et al. Association of extraintestinal manifestations of inflammatory bowel disease in a province western Hungary with disease phenotype: Results of a 25-year follow-up study. World J Gastroenterol 2003;9:2300-7.
15. Grip O, Svensson PJ, Lindgren S. Inflammatory bowel disease promotes venous thrombosis earlier in life. Scand J Gastroenterol 2000;35:619-23.
16. Wakefield A, Cohen Z, Levy G. Procoagulant activity in gastroenterology. Gut 1990;31:239-41.
17. van Aken BE, Reitsma PH, Rosendaal FR. Interleukin 8 and venous thrombosis: Evidence for role of inflammation in thrombosis. Br J Haematol 2002;116:173-7.
18. Souto JC, Martinez E, Roca M, et al. Prothrombotic state and signs of endothelial lesion in plasma of patients with inflammatory bowel disease. Dig Dis Sci 1995;40:1883-9.
19. van Bodegraven AA, Schoorl M, Baak JP, et al. Hemostatic imbalance in active and quiescent ulcerative colitis. Am J Gastroenterol 2001;96:487-93.
20. Conlan MG, Haire WD, Burnett DA. Prothrombotic abnormalities in inflammatory bowel disease. Dig Dis Sci 1989;34:1089-93.
21. Stevens TR, James JP, Simmonds NJ, et al. Circulating von Willebrand factor in inflammatory bowel disease. Gut 1992;33:502-6.
22. Hudson M, Chitolie A, Hutton RA, et al. Thrombotic vascular risk factors in inflammatory bowel disease. Gut 1996;38:733-7.
23. Smith CJ, Haire WD, Kaufman SS, et al. Determination of prothrombin activation fragments in young patients with inflammatory bowel disease. Am J Gastroenterol 1996;91:1221-5.
24. Bjerregaard LT, Nederby NJ, Larsen TB, et al. Platelets and anticoagulant capacity in patients with inflammatory bowel disease. Pathophysiol Haemost Thromb 2002;32:92-6.
25. Saibeni S, Bottasso B, Spina L, et al. Assessment of thrombin-activatable fibrinolysis inhibitor (TAFI) plasma levels in inflammatory bowel diseases. Am J Gastroenterol doi:10.1111/j.1572-0241.2004.30203.x.
26. Bouma BN, Marx PF, Mosnier LO, et al. Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U). Thrombosis Res 2001;101:329-54.
27. Sato T, Miwa T, Akatsu H, et al. Pro-carboxipeptidase R is an acute phase protein in the mouse, whereas carboxypeptidase N is not. J Immunol 2000;165:1053-8.
28. Van Tilburg NH, Rosendaal FR, Bertina RM. Thrombin-activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood 2000;95:2855-9.
29. Eichinger S, Schönauer V, Weltermann A, et al. Thrombin activatable fibrinolysis inhibitor and the risk for recurrent venous thromboembolism. Blood 2004;103:3773-6.
30. Chowers Y, Sela BA, Holland R, et al. Increased levels of homocysteine in patients with Crohn's disease are related to folate levels. Am J Gastroenterol 2000;95:3498-502.
31. Romagnuolo J, Fedorak RN, Dias VC, et al. Hyperhomocysteinemia and inflammatory bowel disease: Prevalence and predictors in a cross-sectional study. Am J Gastroenterol 2001;96:2143-9.
32. Saibeni S, Cattaneo M, Vecchi M, et al. Low vitamin Be plasma levels, a risk factor for thrombosis, in inflammatory bowel disease: Role of inflammation and correlation with acute phase reactants. Am J Gastroenterol 2003;98:112-7.
33. Wakefield AJ, Sawyerr AM, Hudson M, et al. Smoking, the oral contraceptive pill, and Crohn's disease. Dig Dis Sci 1991;36:1147-50.
34. Vermaak WJ, Ubbink JB, Barnard HC, et al. Vitamin B-6 nutrition status and cigarette smoking. Am J Clin Nutr 1990;51:1058-61.
35. Aichbichler BN, Petritsch W, Reicht GA, et al. Anti-cardiolipin antibodies in patients with inflammatory bowel disease. Dig Dis Sci 1999;44:852-6.
36. Papa A, Danese S, Grillo A, et al. Review article: Inherited thrombophilia in inflammatory bowel disease. Am J Gastroenterol 2003;98:1247-51.
37. Novacek G, Miehsler W, Kapiotis S, et al. Thromboembolism and resistance to activated protein C in patients with inflammatory bowel disease. Am J Gastroenterol 1999;94:685-90.
38. Guédon C, Le Cam-Duchez V, Lalaude O, et al. Prothrombotic inherited abnormalities other than factor V Leiden mutation do not play a role in venous thrombosis in inflammatory bowel disease. Am J Gastroenterol 2001;96:1448-54.
39. Welch GN, Loscalzo J. Homocysteine and atheromatosis. N Engl J Med 1998;338:1042-50.
40. Aadland E, Odegaard OR, Roseth A, et al. Free protein S deficiency in patients with Crohn's disease. Scand J Gastroenterol 1994;29:333-5.
41. Godet PG, May GR, Sutherland LR. Meta-analysis of the role of oral contraceptive agents in inflammatory bowel disease. Gut 1995;37:668-78.
42. Vasilopoulos S, Saiean K, Emmons J, et al. Terminal ileum resection is associated with higher plasma homocysteine levels in Crohn's disease. J Clin Gastroenterol 2001;33:132-6.
43. Bjerregaard LT, Nederby NJ, Fredholm L, et al. Hyperhomocysteinemia, coagulation pathway activation and thrombophilia in patients with inflammatory bowel disease. Scand J Gastroenterol 2002;37:62-7.
44. Hommes DW, van Dullemen HM, Levi M, et al. Beneficial effect of treatment with a monoclonal anti-tumor necrosis factor-alpha antibody on markers of coagulation and fibrinolysis in patients with active Crohn's disease. Haemostasis 1997;27:269-77.